http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021085753-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
filingDate 2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3205c57de1e6662d4a5721a2a643f1b8
publicationDate 2021-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2021085753-A1
titleOfInvention Use of a vegf antagonist to treat angiogenic eye disorders
abstract The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11103552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400080-B2
priorityDate 2011-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403802
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26617
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16850
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ99PS1
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID30682
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID407170
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67965
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14254
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GKR0
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID503620
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35968
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395909
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6279
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID558154
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49151
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID796537
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15692
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF6QDM7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A3Q2TVI4
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15691
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID452512
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67860
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395323
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25589
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0K3N4
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID839585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412551
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395317
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID482154
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP67964
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54251
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID461315
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2321
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45157623
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0K3N5
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412552
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID244
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID83785
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3791
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ00731
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7422
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP16612
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281572
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9885981
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9MYV3
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID554230
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2345
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406705
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP50412
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID16542
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393293
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCH0ZCS4
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID544667
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415140
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13109
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID374100
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID22339
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83906
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396304

Total number of triples: 89.